GENE ONLINE|News &
Opinion
Blog

Ionis Pharmaceuticals
Ionis Pharmaceuticals’ Factor XI Reduction Proved Effective in Trial
2022-11-07
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
AstraZeneca, Ionis’ ATTR Drug Edges Closer to US Approval With Latest Trial Win
2022-06-22
AstraZeneca, Ionis Close $3.5+ Billion Deal for Rare Protein Misfolding Disorder
2021-12-30
Ionis’ Once-Monthly Treatment for Rare Hereditary Disease Achieves Trial Endpoints
2021-03-31
JPM Healthcare Conference: Shape, Korro, and Ionis Present Advances in RNA Therapeutics
2021-01-18
Ionis Initiates Phase 3 Trials for Familial Chylomicronemia Syndrome Treatment
2020-12-06
Intellia Trials CRISPR Drug as Permanent Cure to Fatal Hereditary Disease
2020-10-21
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top